CLGN CollPlant Biotechnologies Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLGN

Price (delayed)

$5.95

Market cap

$68.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.62

Enterprise value

$44.63M

collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our ...

Highlights
The revenue has grown by 2.2% from the previous quarter
The company's EPS has surged by 59% YoY but it fell by 5% QoQ
The company's net income has surged by 59% YoY but it fell by 4.3% QoQ
The quick ratio has contracted by 26% from the previous quarter and by 14% YoY
The equity has contracted by 13% from the previous quarter and by 12% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.collplant.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CLGN
Market
Shares outstanding
11.45M
Market cap
$68.14M
Enterprise value
$44.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.4
Price to sales (P/S)
6.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.07
Earnings
Revenue
$10.96M
EBIT
-$7.51M
EBITDA
-$6.41M
Free cash flow
-$3.65M
Per share
EPS
-$0.62
Free cash flow per share
-$0.32
Book value per share
$2.47
Revenue per share
$0.96
TBVPS
$2.98
Balance sheet
Total assets
$34.13M
Total liabilities
$5.79M
Debt
$3.16M
Equity
$28.34M
Working capital
$24.77M
Liquidity
Debt to equity
0.11
Current ratio
8.62
Quick ratio
8.33
Net debt/EBITDA
3.67
Margins
EBITDA margin
-58.5%
Gross margin
81.8%
Net margin
-64%
Operating margin
-68.5%
Efficiency
Return on assets
-18.8%
Return on equity
-22.2%
Return on invested capital
-66.6%
Return on capital employed
-24.3%
Return on sales
-68.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLGN stock price

How has the CollPlant Biotechnologies stock price performed over time
Intraday
-4.49%
1 week
1.54%
1 month
9.07%
1 year
-13.77%
YTD
-6.89%
QTD
11.21%

Financial performance

How have CollPlant Biotechnologies's revenue and profit performed over time
Revenue
$10.96M
Gross profit
$8.97M
Operating income
-$7.51M
Net income
-$7.02M
Gross margin
81.8%
Net margin
-64%
The operating margin has soared by 99% YoY but it has contracted by 3.2% from the previous quarter
The net margin has soared by 99% YoY
The company's net income has surged by 59% YoY but it fell by 4.3% QoQ
CollPlant Biotechnologies's operating income has surged by 56% YoY but it has decreased by 6% QoQ

Growth

What is CollPlant Biotechnologies's growth rate over time

Valuation

What is CollPlant Biotechnologies stock price valuation
P/E
N/A
P/B
2.4
P/S
6.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.07
The company's EPS has surged by 59% YoY but it fell by 5% QoQ
The P/B is 50% less than the 5-year quarterly average of 4.8
The equity has contracted by 13% from the previous quarter and by 12% YoY
CLGN's price to sales (P/S) is 88% lower than its 5-year quarterly average of 51.0 and 82% lower than its last 4 quarters average of 35.0
The revenue has grown by 2.2% from the previous quarter

Efficiency

How efficient is CollPlant Biotechnologies business performance
The company's return on sales has surged by 99% YoY but it fell by 9% QoQ
The ROIC has soared by 68% YoY but it has contracted by 13% from the previous quarter
CLGN's ROA has soared by 52% year-on-year but it is down by 7% since the previous quarter
CollPlant Biotechnologies's ROE has soared by 51% YoY but it has decreased by 8% from the previous quarter

Dividends

What is CLGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLGN.

Financial health

How did CollPlant Biotechnologies financials performed over time
The current ratio has declined by 27% since the previous quarter and by 15% year-on-year
The quick ratio has contracted by 26% from the previous quarter and by 14% YoY
The debt is 89% less than the equity
CollPlant Biotechnologies's debt to equity has increased by 22% YoY and by 10% QoQ
The equity has contracted by 13% from the previous quarter and by 12% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.